Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Hosted on MSN15h
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
FierceBiotech17h
Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
ncbiotech.org17h
IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
Novo Nordisk A/S Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NVO
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in ...